News

Lonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic Acidemia

Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases that avoid unwanted immunogenicity, have entered into a strategic manufacturing agreement. Under the terms of the agreement, Lonza will produce an Anc80-AAV-based gene therapy product for Selecta’s proprietary program for the treatment of Methylmalonic Acidemia (MMA), a rare inborn error of metabolism, and may in the future produce other…

Almatec® Featuring BIOCOR Series Pumps at INTERPHEX 2017

Almatec®, part of PSG®, a Dover company and premier manufacturer of sanitary air-operated double-diaphragm (AODD) pumps, will be featuring its BIOCOR Series pumps for sterile applications in Booth 2253 at INTERPHEX 2017. The INTERPHEX event brings together a wide variety of leaders from the pharmaceutical and biotech industries and will be held at the Jacob K. Javits Convention Center in New York, NY, USA, from March 21-23. BIOCOR pumps from Almatec have been specifically designed for critical biotech and pharmaceutical…

Rentschler and Leukocare Announce Formulations Strategic Alliance and Equity Investment

Rentschler Biotechnologie GmbH, Laupheim and Leukocare AG, Martinsried today announced a strategic alliance under which Leukocare will become the specialized technology partner and the exclusive formulation developer for Rentschler’s biopharmaceuticals business. Rentschler in return will become the first and only contract development and manufacturing organization (CDMO) to have access to Leukocare´s patented SPS® formulation technologies. Leukocare’s ongoing and future business activities with pharma and biotech beyond the CDMO business will not be affected by this alliance. Rentschler will acquire a…

Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform

Servier, the independent international pharmaceutical company, and MaSTherCell SA, the full-service contract development and manufacturing organization (CDMO) specializing in the delivery of optimized process industrialization capacities to cell therapy organizations, today announced the signing of a master service agreement for the development of a manufacturing platform for allogeneic cell therapies. Under the master service agreement, MaSTherCell is developing a CAR-T cell therapy manufacturing platform, which will enable industrial and commercial manufacturing of Servier cell therapy products. This is a critical…

Vetter Starts Operations in its Center for Visual Inspection and Logistics

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO) for development, aseptic filling and final packaging of injectables, has announced today that it has begun operations in its expanded Visual Inspection and Logics Center located in Ravensburg. The enlargement, in which the company invested approximately 100 million euros ($107 million), bundles capacity for final product inspection and logistics in one cutting-edge site. By finalizing the second construction stage of the site that was initially put into operation five years…

MilliporeSigma Launches First Commercial Service to Predict Multiple Sources of DNA Damage

MilliporeSigma has introduced CAN MultiFlow™ screening services to more accurately predict genotoxic and mode of action* properties of substances, ingredients and drug compounds. Offered through its BioReliance® testing facilities, MilliporeSigma will be the first company to provide this service in the United States. The screening process uses flow cytometry to quickly and efficiently screen for clastogens, aneugens and non-genotoxicants (CAN) in pharmaceutical compounds, agricultural chemicals, flavors, fragrances and consumer products. The results from the assay can help manufacturers reject harmful…

MilliporeSigma Expands End-to-End Biodevelopment Centers in North America, China and Europe

MilliporeSigma, a leading science and technology company, today announced the expansion of its end-to-end biodevelopment centers to meet increasing customer demand for its turnkey portfolio of bioprocessing products, manufacturing capabilities and industry leading technological expertise. The expansion, which includes the opening of two new process development centers in the U.S. and China, follows the commercial success of MilliporeSigma’s biodevelopment center in Martillac, France. The two new units will be located in close proximity to customers in the Shanghai and Boston…

Qosina Adds New Y Connector Hemostasis Valves

Qosina is pleased to announce the addition of four new Y connector hemostasis valves (#80300-#80303) to its product line. Each hemostasis valve is equipped with a rotating male luer lock or male luer slip, and a female luer lock sideport. The Y connector gives the valve an ergonomic design for comfortable handling. The housing is made from a tinted polycarbonate material that minimizes discoloration during the sterilization process. The silicone gasket creates a seal for secure positioning when closed and…

Saint-Gobain Opens New Maryland Facility to Manufacture Single-Use Systems for Cell Therapy

Saint-Gobain Performance Plastics’ Life Sciences Division is celebrating its move into the fast-growing cell therapy market with a new state-of-the-art facility that will manufacture specialty disposables for both the cell therapy and biotechnology markets. With material technology combined with expertise in custom design, Saint-Gobain Performance Plastics is uniquely positioned to offer solutions to the numerous challenges faced by cell therapy manufacturers today, contributing to the end goal of delivering effective therapies to more patients. Located in Gaithersburg, Maryland, the new…

Lonza to Divest Peptides Business and Operations in Braine-l’Alleud, Belgium, to PolyPeptide

Lonza and the PolyPeptide Group jointly announced today that PolyPeptide Laboratories Holding (PPL) has entered into a definitive agreement with Lonza Sales AG and Lonza AG (both 100% affiliates of Lonza Group AG) to acquire the peptides business and operations of Lonza in Braine-l’Alleud, Belgium. Lonza’s Braine facility, with approximately 280 employees, is the center for peptide chemical development and manufacturing within Lonza. The agreement is expected to close in the next weeks, subject to customary closing conditions. The acquisition…